Niagen Bioscience (NAGE) FCF Margin (2011 - 2026)
Niagen Bioscience (NAGE) posted quarterly FCF Margin of 3.79% for Q1 2026, down 2966.0% year-over-year from 0.13% in Q1 2025, and down 282.35% quarter-over-quarter from 2.08% in Q4 2025.
Niagen Bioscience (NAGE) FCF Margin (2011 - 2026) Analysis & Trends
Niagen Bioscience (NAGE) has reported FCF Margin for 14 consecutive years, with 3.79% the latest figure, recorded in Q1 2026.
- In Q1 2026, FCF Margin fell 2966.0% year-over-year to 3.79%; the TTM figure through Mar 2026 stood at 3.39% (down 1486.0% YoY), while the FY2025 annual figure was 10.43%, down 172.0% from the prior year.
- FCF Margin retreated to 3.79% in Q1 2026 per NAGE's latest filing, from 2.08% in the prior quarter.
- Across five years, FCF Margin topped out at 29.47% in Q4 2024 and bottomed at 41.71% in Q1 2022.
- Historically, FCF Margin has averaged 1.63% across 5 years, with a median of 2.08% in 2025.
- Annual changes were most pronounced in 2023 — FCF Margin jumped 5408 bps — and 2026, when it plunged 2966 bps.
- Niagen Bioscience's FCF Margin stood at 1.56% in 2022, then soared by 296 bps to 3.06% in 2023, then surged by 862 bps to 29.47% in 2024, then slumped by 93 bps to 2.08% in 2025, then plunged by 282 bps to 3.79% in 2026.
- Business Quant data shows NAGE's FCF Margin at 3.79% in Q1 2026, 2.08% in Q4 2025, and 10.89% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,594.17% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 70.82% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.62% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -22.35% |
| 10 | Niagen Bioscience | 238.30 Mn | 171.56 Mn | 19.31 Mn | 9.31% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.31% |
| Mar 31, 2026 | -3.79% |
| Dec 31, 2025 | 2.08% |
| Sep 30, 2025 | 10.89% |
| Jun 30, 2025 | 3.91% |
| Mar 31, 2025 | 25.86% |
| Dec 31, 2024 | 29.47% |
| Sep 30, 2024 | 13.66% |
| Jun 30, 2024 | -1.16% |
| Mar 31, 2024 | 1.33% |
| Dec 31, 2023 | 3.06% |
| Sep 30, 2023 | 2.03% |
| Jun 30, 2023 | 16.14% |
| Mar 31, 2023 | 12.38% |
| Dec 31, 2022 | -1.56% |
| Sep 30, 2022 | -21.92% |
| Jun 30, 2022 | -22.90% |
| Mar 31, 2022 | -41.71% |
| Dec 31, 2021 | -27.84% |
| Sep 30, 2021 | -34.20% |